Global Information
회사소개 | 문의 | 위시리스트

급성 호흡곤란 증후군(ARDS) : 파이프라인 리뷰

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 192441
페이지 정보 영문 111 Pages
가격
US $ 2,000 ₩ 2,308,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,616,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,924,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


급성 호흡곤란 증후군(ARDS) : 파이프라인 리뷰 Acute Respiratory Distress Syndrome - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 111 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

급성 호흡곤란 증후군(ARDS)은 폐안의 작은 탄력적 공기낭(폐포)에 체액이 고이면서 발생합니다. 흔히 볼 수 있는 근본적인 원인으로 패혈증, 유해물질 흡입, 중증 폐렴, 두부 및 흉부의 외상 등을 들 수 있습니다. 징후와 증상은 중도의 숨참, 호흡곤란, 비정상적으로 빠른 호흡, 저혈압, 정신착란, 극도의 피로 등입니다.

급성 호흡곤란 증후군(ARDS)에 대한 치료제 개발 상황에 대해 조사분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 대한 정보를 정리하여 전해드립니다.

목차

서론

급성 호흡곤란 증후군(ARDS) 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

개발중인 치료제 : 기업별

조사중인 치료제 : 대학/연구기관별

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상시험 단계 제품
  • 초기 단계 제품

개발중인 제품 : 기업별

조사중인 제품 : 대학/연구기관별

치료제 개발에 참여하고 있는 기업

  • Altor BioScience Corporation
  • Athersys, Inc.
  • Faron Pharmaceuticals Oy
  • FirstString Research, Inc.
  • GlaxoSmithKline Plc
  • Histocell S.L.
  • Phylogica Limited
  • Serendex Pharmaceuticals A/S
  • Silence Therapeutics Plc
  • Therabron Therapeutics, Inc.

치료제 평가

  • 단일요법의 경우
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

  • ALT-836
  • BIO-10901
  • CG-367
  • Cyndacel-M
  • GSK-2586881
  • GSK-2862277
  • 인터페론β-1a
  • molgramostim
  • 감염증·호흡기질환용 uPA 저해 모노클로널 항체
  • 폐동맥 고혈압용 Endothelin-1 저해 올리고뉴클레오티드
  • PF-05285401
  • PYC-35
  • PYC-36
  • PYC-38
  • PYC-98
  • 급성 폐손상·급성 호흡곤란 증후군용 재조합단백질
  • S-1229
  • SAN-101
  • 면역학·호흡기/근골격 장애용 MMP·사이토카인 저해소분자
  • 염증성 폐질환용 줄기세포 요법
  • 급성 호흡곤란 증후군용 간질세포 요법
  • 급성 폐손상·급성 호흡곤란 증후군용 합성 펩티드

파이프라인 제품의 최신 동향

휴지 상태 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

도표

KSA 16.04.08

List of Tables

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Bayer AG, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Cells for Cells SA, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by CompleGen Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Cynata Therapeutics Ltd, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Meridigen Biotech Co Ltd, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by PaxVax Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by ProMetic Life Sciences Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Dormant Projects, H1 2019
  • Acute Respiratory Distress Syndrome - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Acute Respiratory Distress Syndrome - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Top 10 Molecule Types, H1 2019
  • Number of Products by Stage and Top 10 Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2019, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 7, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Acute Respiratory Distress Syndrome - Overview
  • Acute Respiratory Distress Syndrome - Therapeutics Development
  • Acute Respiratory Distress Syndrome - Therapeutics Assessment
  • Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
  • Acute Respiratory Distress Syndrome - Drug Profiles
  • Acute Respiratory Distress Syndrome - Dormant Projects
  • Acute Respiratory Distress Syndrome - Discontinued Products
  • Acute Respiratory Distress Syndrome - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q
 
BCC Research